Information:
Fel:
ID
12178
Beskrivning
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.; ODM derived from: https://clinicaltrials.gov/show/NCT02097849
Länk
https://clinicaltrials.gov/show/NCT02097849
Nyckelord
Versioner (1)
- 2015-10-07 2015-10-07 - Julian Varghese
Uppladdad den
7 oktober 2015
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Relapsing Forms of Multiple Sclerosis NCT02097849
Eligibility Relapsing Forms of Multiple Sclerosis NCT02097849
- StudyEvent: Eligibility
Similar models
Eligibility Relapsing Forms of Multiple Sclerosis NCT02097849
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
confirmed diagnosis of rrms
Item
must have a confirmed diagnosis of rrms per the 2010 mcdonald criteria.
boolean
C0751967 (UMLS CUI [1])
tetanus immunization
Item
must have a known tetanus immunization history with most recent tetanus vaccination given 2 to 15 years prior to screening and an anti-tetanus igg titer at screening that is less than or equal to one-half the upper limit of detection for the assay.
boolean
C0199807 (UMLS CUI [1])
C0305058 (UMLS CUI [2])
C0305058 (UMLS CUI [2])
Tecfidera | Avonex | Betaseron | Rebif | Extavia
Item
must have been on a stable approved dose of tecfidera (240 mg twice daily [bid]) [group 1] for ≥6 months or on a stable approved dose of a non-pegylated ifn (e.g., avonex, betaseron, rebif, extavia) [group 2] for ≥3 months prior to day 1.
boolean
C3556178 (UMLS CUI [1])
C0594372 (UMLS CUI [2])
C0284968 (UMLS CUI [3])
C0752980 (UMLS CUI [4])
C2719461 (UMLS CUI [5])
C0594372 (UMLS CUI [2])
C0284968 (UMLS CUI [3])
C0752980 (UMLS CUI [4])
C2719461 (UMLS CUI [5])
clinical relapse requiring treatment
Item
clinical relapse requiring treatment within 30 days prior to day 1.
boolean
C0856120 (UMLS CUI [1,1])
C0815189 (UMLS CUI [1,2])
C0815189 (UMLS CUI [1,2])
pneumococcal vaccination; screening
Item
pneumococcal vaccination within 5 years prior to screening.
boolean
C0419707 (UMLS CUI [1])
meningococcal vaccines; exposure
Item
previous exposure to meningococcal vaccines.
boolean
C0700144 (UMLS CUI [1])
C0332157 (UMLS CUI [2])
C0332157 (UMLS CUI [2])
hypersensitivity to td, ppsv23, or mcv4 or their components.
Item
known hypersensitivity to td, ppsv23, or mcv4 or their components.
boolean
C0020517 (UMLS CUI [1,1])
C3272755 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0358314 (UMLS CUI [2,2])
C3272755 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0358314 (UMLS CUI [2,2])
other protocol-defined inclusion/exclusion criteria may apply
Item
note: other protocol-defined inclusion/exclusion criteria may apply.
boolean
C2827031 (UMLS CUI [1])